MAIA Biotechnology (MAIA) Change in Account Payables (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Change in Account Payables of $940877.0 for Q1 2026, up 162.03% year-over-year from $359070.0 in Q1 2025, and up 182.64% quarter-over-quarter from -$1.1 million in Q4 2025.
MAIA Biotechnology (MAIA) Change in Account Payables (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Change in Account Payables for 6 consecutive years, with $940877.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 162.03% year-over-year to $940877.0; the TTM figure through Mar 2026 stood at $1.1 million (up 34055.88% YoY), while the FY2025 annual figure was $519720.0, up 537.38% from the prior year.
- Change in Account Payables grew to $940877.0 in Q1 2026 per MAIA's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q3 2025 and bottomed at -$1.1 million in Q4 2025.
- Historically, Change in Account Payables has averaged $119118.4 across 5 years, with a median of $146558.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables plunged 1127.42% — and 2025, when it surged 1358.96%.
- MAIA Biotechnology's Change in Account Payables stood at $146558.0 in 2022, then surged by 178.31% to $407881.0 in 2023, then fell by 9.46% to $369308.0 in 2024, then plunged by 408.28% to -$1.1 million in 2025, then jumped by 182.64% to $940877.0 in 2026.
- Business Quant data shows MAIA's Change in Account Payables at $940877.0 in Q1 2026, -$1.1 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -144,773.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -144,773.00 |
| Jun 30, 2026 | -144,773.00 |
| Mar 31, 2026 | 940,877.00 |
| Mar 31, 2026 | 940,877.00 |
| Dec 31, 2025 | -1.14 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | -153,039.00 |
| Jun 30, 2025 | -153,039.00 |
| Mar 31, 2025 | 359,070.00 |
| Mar 31, 2025 | 359,070.00 |
| Dec 31, 2024 | 369,308.00 |
| Dec 31, 2024 | 369,308.00 |
| Sep 30, 2024 | -115,349.00 |
| Sep 30, 2024 | -115,349.00 |
| Jun 30, 2024 | -609,804.00 |
| Jun 30, 2024 | -609,804.00 |
| Mar 31, 2024 | 237,018.00 |
| Mar 31, 2024 | 237,018.00 |